GR3035227T3 - Neuroactive peptides - Google Patents

Neuroactive peptides

Info

Publication number
GR3035227T3
GR3035227T3 GR20010400043T GR20010400043T GR3035227T3 GR 3035227 T3 GR3035227 T3 GR 3035227T3 GR 20010400043 T GR20010400043 T GR 20010400043T GR 20010400043 T GR20010400043 T GR 20010400043T GR 3035227 T3 GR3035227 T3 GR 3035227T3
Authority
GR
Greece
Prior art keywords
neuroactive peptides
specific identification
neuroactive
peptides
nmda
Prior art date
Application number
GR20010400043T
Other languages
English (en)
Inventor
Joseph R Moskal
Hirotaka Yamamoto
Patricia A Colley
Original Assignee
Neurotherapeutics L P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurotherapeutics L P filed Critical Neurotherapeutics L P
Publication of GR3035227T3 publication Critical patent/GR3035227T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0823—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GR20010400043T 1996-05-17 2001-01-11 Neuroactive peptides GR3035227T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/649,272 US5763393A (en) 1996-05-17 1996-05-17 Neuroactive peptides
PCT/US1997/008667 WO1997043306A1 (en) 1996-05-17 1997-05-16 Neuroactive peptides

Publications (1)

Publication Number Publication Date
GR3035227T3 true GR3035227T3 (en) 2001-04-30

Family

ID=24604116

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20010400043T GR3035227T3 (en) 1996-05-17 2001-01-11 Neuroactive peptides

Country Status (12)

Country Link
US (2) US5763393A (el)
EP (2) EP0914331B1 (el)
JP (1) JP2000501746A (el)
AT (1) ATE197307T1 (el)
AU (1) AU3209097A (el)
CA (1) CA2255659C (el)
DE (1) DE69703449T2 (el)
DK (1) DK0914331T3 (el)
ES (1) ES2153671T3 (el)
GR (1) GR3035227T3 (el)
PT (1) PT914331E (el)
WO (1) WO1997043306A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098367A2 (en) * 2000-06-22 2001-12-27 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
WO2003010540A1 (en) * 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
EP2331571B1 (en) 2008-09-18 2015-08-26 Northwestern University Nmda receptor modulators and uses thereof
PL2985032T3 (pl) 2009-10-05 2019-07-31 Northwestern University Glyx do stosowania do leczenia choroby alzheimera, choroby parkinsona lub choroby huntingtona
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
SG10201811584RA (en) 2010-02-11 2019-01-30 Univ Northwestern Secondary Structure Stabilized NMDA Receptor Modulators And Uses Thereof
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
SG10202010665YA (en) 2011-04-27 2020-11-27 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
US8798716B1 (en) 2011-11-03 2014-08-05 Solstice Corporation Fiducial markers and related methods
US8974365B2 (en) 2012-11-25 2015-03-10 Steven Richard Devore Best Treatment of thalamocortical dysrhythmia
DK2948140T3 (en) 2013-01-22 2017-08-21 Vistagen Therapeutics Inc DOSAGE FORMS AND THERAPEUTIC APPLICATIONS OF L-4-CHLORCYNURENINE
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
HUE043843T2 (hu) 2013-01-29 2019-09-30 Aptinyx Inc Spiro-laktám NMDA receptor modulátorok és azok alkalmazása
CA2898863A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
AU2014212485C1 (en) 2013-01-29 2018-10-25 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2014212501A1 (en) 2013-01-29 2015-07-30 Aptinyx, Inc. Spiro-lactam NMDA receptor modulators and uses thereof
GB201319437D0 (en) * 2013-11-04 2013-12-18 Nanomerics Ltd Delivery of drugs
BR112016024841A2 (pt) 2014-04-25 2017-10-24 Naurex Inc composições estáveis de peptídeos neuroativos
US9994614B2 (en) * 2014-07-24 2018-06-12 Naurex, Inc. N-methyl-D-aspartate receptor modulators and methods of making and using same
SG11201701134XA (en) 2014-08-14 2017-03-30 Naurex Inc Methods of treating depression using nmda modulators
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
BR112019001768A2 (pt) 2016-08-01 2019-06-11 Aptinyx Inc moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BR112019001926A2 (pt) 2016-08-01 2019-08-06 Aptinyx Inc moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes
CA3031534C (en) 2016-08-01 2023-10-17 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP7032378B2 (ja) 2016-08-01 2022-03-08 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子及びその使用
EP3490990B1 (en) 2016-08-01 2023-12-06 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda modulators and methods of using same
JP2021512857A (ja) 2017-11-10 2021-05-20 ノーレックス インコーポレイテッド Ｎｍｄａ受容体アゴニストの投与方法
CN111670041A (zh) 2017-12-05 2020-09-15 诺雷克斯股份有限公司 用在组合疗法(睡眠障碍或中枢神经系统障碍)中的nmda受体调节剂(拉帕斯汀)组合
WO2019152687A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) * 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
JPH07101999A (ja) * 1993-10-06 1995-04-18 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体に対する抗イデイオタイプ抗体のアミノ酸配列およびそれをコードするｄｎａ塩基配列

Also Published As

Publication number Publication date
ATE197307T1 (de) 2000-11-15
PT914331E (pt) 2001-04-30
EP0914331A1 (en) 1999-05-12
EP1077217A3 (en) 2004-01-02
JP2000501746A (ja) 2000-02-15
CA2255659C (en) 2005-03-15
US6107271A (en) 2000-08-22
ES2153671T3 (es) 2001-03-01
WO1997043306A1 (en) 1997-11-20
EP1077217A2 (en) 2001-02-21
DE69703449T2 (de) 2001-06-07
US5763393A (en) 1998-06-09
CA2255659A1 (en) 1997-11-20
EP0914331B1 (en) 2000-11-02
DE69703449D1 (de) 2000-12-07
AU3209097A (en) 1997-12-05
DK0914331T3 (da) 2001-02-12

Similar Documents

Publication Publication Date Title
GR3035227T3 (en) Neuroactive peptides
GB9921155D0 (en) Selection system
AUPN999096A0 (en) Peptides, antibodies, vaccines & uses thereof
EP1004674A4 (en) HUMAN ADAMTS-1 PROTEIN, GENE ENCODING THE SAME, PHARMACEUTICAL COMPOSITION AND IMMUNOLOGICAL ASSAY FOR HUMAN ADAMTS-1 PROTEIN
WO1999025843A3 (en) Human checkpoint kinase, hcds1, compositions and methods
AU9744898A (en) Synthetic polypeptide for diagnosing and treating prion-related diseases
AU7247896A (en) Protein signature analysis
WO1997045746A3 (en) Prion protein binding proteins and uses thereof
HK1001207A1 (en) Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
HK1041290A1 (en) Novel tumor antigen protein sart-3 and tumor antigen peptide thereof
AU4824197A (en) Novel human lim proteins
GB9816514D0 (en) Novel method
IL139604A (en) Fibrinogen-beta chain derived peptide, compositions comprising same and use thereof
AUPN720195A0 (en) Equine rhinovirus 1 proteins
ATE221204T1 (de) Rezeptorbindungsassay, für den rezeptorbindungsassay geeigneter rekombinanter fusionsrezeptor, vektor zu dessen herstellung sowie reagenziensatz für die durchführung des rezeptorbindungsassays
AU5692699A (en) Apparatus for rapid protein and polypeptide sequence analysis
ZA978472B (en) Cysteine analogue containing peptides.
AU5137698A (en) Novel dna, novel protein, and novel antibody
AU3414095A (en) Lysine/leucine polypeptides, mixture sets and libraries thereof
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
AU2771397A (en) Phenylcarbamates, methods for preparing them and agents containing them
GB2311783B (en) Polypeptides derived from wasp protein
EP1186662A3 (en) Prion binding proteins and uses thereof
ZA979405B (en) Process for isolating a protein composition from a muscle source and protein composition.
GB2311067B (en) Proline rich peptides derived from the rasgap-associated protein P62

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees